Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management
-
May 24, 2026, 05:47Ali AlBahar: The Immunologic Complexity Behind ABO Blood Grouping
-
May 24, 2026, 05:46Ghaith Mansour: Honoring Scientific Collaboration at the 7th Pharmacy Research and Innovation Day
-
May 24, 2026, 04:57Ahmed Elsobky: Strengthening Hemophilia Care Under Egypt’s Universal Health Insurance System
-
May 24, 2026, 04:49Hussien Hishmat: There Is More to Pulmonary Embolism than Just Anticoagulation
-
May 24, 2026, 04:25Sarah Elkourashy: Diagnostic Challenges and Management Strategies for Maternal–Fetal Outcomes in TTP
-
May 24, 2026, 04:11Ayah Ghazi Al-Qasrawi: How Should Sepsis-Induced DIC Be Managed in Patients Receiving Thienopyridines
-
May 24, 2026, 04:05Kate Hayward: Recent Stroke Recovery and Rehabilitation Highlights